Cardiovascular Optimisation Protocol

Advanced cardiovascular workup and integrative optimisation for Indian adults concerned about heart health — working alongside your cardiologist, not replacing them.

At a Glance

What it targets: The biology that drives cardiovascular risk in South Asians — elevated lipoprotein(a), residual inflammation, metabolic dysfunction, oxidative stress, mitochondrial decline, and endothelial dysfunction — with advanced biomarker testing that goes beyond the standard cholesterol panel.

Who it’s for: Adults 35-75 with family history of early heart disease, abnormal lipids, hypertension, diabetes, post-cardiac-event status (post-MI, post-stent, post-CABG, heart failure), or wanting deeper risk insight than routine testing provides.

How it works: Physician-led combination of advanced workup, autologous cell therapy for confirmed CVD, mitochondrial and cellular energy support, and vascular repair and endothelial work — anchored by lifestyle and metabolic foundation.

What to expect: Biomarker improvements typically appear over 3-6 months. ALIV does not diagnose, treat, or prevent cardiovascular disease, and does not replace any prescribed cardiology care. The goal is biology-informed optimisation alongside your specialist.

Who This Protocol Is For

South Asians carry one of the highest cardiovascular disease risks of any ethnic group globally — with earlier onset, more aggressive progression, and higher mortality than Western populations. A 2025 Indian SR/MA estimated the pooled CVD prevalence at 11%, rising to 12% in urban populations. Standard cardiology care — statins, antihypertensives, antiplatelets, lifestyle counselling — saves lives but is rarely the whole story. Many patients seek advanced cardiac care, additional therapies after a heart attack, or alternative regenerative treatment for heart disease. This protocol layers those: advanced biomarker testing (lipoprotein(a), hsCRP, ApoB — Lp(a) is elevated in roughly one in four South Asians and missed by routine panels), autologous cell therapy for confirmed CVD, mitochondrial and cellular energy support, and peptide-based vascular repair. The Ridker 2024 NEJM 30-year analysis confirmed LDL, hsCRP, and Lp(a) together provide far stronger risk stratification than any one biomarker alone.

This protocol was built for you if:

• You have a family history of early heart attack, stroke, or sudden cardiac death
• Your lipid panel shows elevated LDL, low HDL, or high triglycerides
• You have hypertension, type 2 diabetes, prediabetes, or metabolic syndrome
• You’ve had a cardiac event (MI, stent, bypass) or have heart failure/cardiomyopathy and want integrative regenerative support alongside your cardiology care
• You’ve never had your lipoprotein(a) or hsCRP tested — standard workup almost never includes them
• You want deeper biomarker insight than routine annual health checks provide

Important: This protocol is integrative supportive care, not replacement. If you are under cardiology care, all prescribed medications — statins, antihypertensives, antiplatelets, anticoagulants — must be continued as directed. ALIV coordinates with your cardiologist. Acute cardiac symptoms (chest pain, breathlessness, palpitations) require emergency medical evaluation, not this protocol.

How It Works — The ALIV Approach

Cardiovascular risk is multi-factorial: cholesterol particle biology, inherited Lp(a), chronic inflammation, glycemic burden, oxidative stress, mitochondrial function, and endothelial integrity all interact. Standard cardiology screens for some. This protocol layers the rest — alongside your cardiologist’s prescribed care, shaped to your individual biology and risk profile.

Layer 1 — Advanced Workup and Diagnostic Precision

Beyond the standard lipid panel, your ALIV physician runs: lipoprotein(a) — inherited, critical to know; hsCRP for residual inflammatory risk; ApoB as the truer marker of atherogenic particle burden than LDL alone; LDL particle size; HbA1c and fasting insulin; homocysteine; vitamin D; B12; ferritin; thyroid panel; uric acid. Where indicated, coronary calcium scoring is recommended through your cardiologist for structural plaque burden assessment.

Layer 2 — Autologous Cell Therapy (For Confirmed Cardiovascular Disease)

For individuals with confirmed CVD — post-MI, post-stent, post-CABG, ischemic cardiomyopathy, heart failure with reduced ejection fraction — ALIV’s autologous cell therapy is the regenerative pillar. Growing SR/MA evidence shows cell-based cardiac repair can improve left ventricular ejection fraction and reduce infarct size, with mechanisms including angiogenesis stimulation, paracrine growth factor signalling, and support of resident cardiomyocyte survival. Reserved for selected clients after diagnostic workup and cardiology coordination; investigational; outcomes vary; not a replacement for cardiology-prescribed treatment.

Layer 3 — Mitochondrial and Cellular Energy

Cardiomyocyte and endothelial cell function are mitochondria-intensive. Bioenergetic decline is one of the under-recognised aspects of cardiovascular aging. The protocol provides: CoQ10/Ubiquinol — a central piece of this layer, particularly important if on statin therapy, which depletes endogenous CoQ10 production; NAD+ precursors (NMN/NR); ALIV’s NAD+ Vitality IV for bioavailable cellular energy support; and — for individuals with significant mitochondrial decline — SS-31, a peptide that stabilises cardiolipin in the inner mitochondrial membrane to restore mitochondrial efficiency.

Layer 4 — Vascular Repair and Endothelial Support

Residual inflammatory risk — elevated hsCRP despite optimal LDL control — is one of the major frontiers in modern cardiology. The protocol layers nutrition, supplement, and peptide interventions targeting the inflamed, ageing endothelium. Foundations: omega-3 (EPA/DHA), polyphenol-rich nutrition, gut microbiome work (coordinates with the Gut Barrier Protocol), targeted micronutrients (magnesium, vitamin D, vitamin K2). Peptide layer: Thymosin Alpha-1 supports the cardio-immune axis; BPC-157 supports endothelial repair and angiogenesis in early research; GHK-Cu, a copper peptide with documented anti-inflammatory and tissue-remodelling properties, can be added in selected cases. All peptides used case-by-case as investigational adjuncts.

What to Expect

The Lifestyle Layer — Non-Negotiable

Smoking cessation: the single highest-impact intervention; non-negotiable. Glycemic and metabolic foundation: insulin resistance, metabolic syndrome, and visceral fat are core CVD drivers in the South Asian phenotype — the protocol coordinates with the Advanced Metabolic Reset Protocol where appropriate, including Tirzepatide pathway where indicated. Nutrition: Mediterranean-style or DASH pattern, abundant vegetables, oily fish, nuts, olive oil; reduced refined carbohydrates and processed foods. Movement: structured aerobic and resistance training appropriate to your cardiology clearance. Sleep: 7-8 hours, OSA screening if indicated. Stress, alcohol minimisation, annual biomarker review.

Frequently Asked Questions

Does this replace my cardiologist or my heart medications?

No. This protocol is strictly integrative care alongside your cardiologist. All prescribed medications — statins, antihypertensives, antiplatelets, anticoagulants — must be continued as directed. ALIV does not prescribe or modify cardiology medications.

Why test lipoprotein(a)? My doctor never mentioned it.

Lp(a) is inherited and elevated in roughly one in four South Asians, contributing to the earlier-onset heart disease seen in this population. It is not in routine Indian lipid panels but is one of the strongest independent risk factors identified in cardiology in recent decades. Even when LDL is well-controlled with statins, elevated Lp(a) drives residual risk. Knowing your number is a one-time test (Lp(a) is genetically stable across life) that changes how aggressively to address the modifiable factors around it.

Can ALIV prevent a heart attack?

No — and any clinic claiming this is misleading you. ALIV offers biology-informed optimisation that addresses modifiable risk factors. Outcome prevention belongs to clinical trials, statins, antihypertensives, and lifestyle changes — layered through your cardiologist’s ongoing care.

Is this just for people with existing heart disease?

No. Many clients are healthy adults with family history, abnormal lipids, or simply wanting deeper insight than routine workup provides. Earlier engagement allows earlier intervention on modifiable factors.

Can heart disease be reversed?

Honestly: established atherosclerotic plaque is not fully reversible with any current therapy, including stem cell or regenerative interventions. What can change: progression can be slowed or halted with aggressive risk-factor management, plaque can stabilise, inflammation can be reduced, ejection fraction can improve in heart failure cases (where autologous cell therapy has evidence). “Reverse” is a marketing word; “optimise and stabilise” is the honest one.

What are the alternative treatments for heart disease beyond medication?

Standard cardiology medication is the foundation and not optional. “Alternative” framing is unhelpful — “additional” is more accurate. Evidence-supported additional layers: advanced biomarker testing (Lp(a), hsCRP, ApoB), autologous cell therapy for confirmed CVD, mitochondrial support, anti-inflammatory nutrition, peptide therapies, and lifestyle change. ALIV provides these alongside, not instead of, your cardiologist’s treatment.

Who should NOT do this protocol?

Anyone with acute cardiac symptoms requiring emergency evaluation; severe uncontrolled hypertension or heart failure requiring primary medical stabilisation; clients seeking to replace or stop cardiology-prescribed medications.

Take the Next Step

Cardiovascular disease is the leading cause of death in India — and in South Asians, the risk profile starts earlier and progresses faster than in most other populations. Advanced biomarker testing and integrative optimisation, working alongside your cardiologist, can meaningfully sharpen the picture.

To find out if the Cardiovascular Optimisation Protocol is right for you, speak with our medical team:

• Pune (Bund Garden): +91 77199 88811
• Mumbai (Khar West): +91 98220 93069

Or book a consultation through alivtherapy.in.

Research References

1. Shannawaz M, Rathi I, Shah N, Saeed S, Chandra A, Singh H. Prevalence of CVD Among Indian Adult Population: Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2025;22(4):539. PMID: 40283763

2. Ridker PM, Moorthy MV, Cook NR, Rifai N, Lee IM, Buring JE. Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women. N Engl J Med. 2024;391:2087-2097. PMID: 39216091

3. Aday AW, Ridker PM. Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease. Front Cardiovasc Med. 2019;6:16. DOI: 10.3389/fcvm.2019.00016

4. Birk AV, Liu S, Soong Y, Mills W, Singh P, Warren JD, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250-61. PMID: 23813215

5. Abouzid MR, Umer AM, Jha SK, Akbar UA, Khraisat O, Saleh A, et al. Stem Cell Therapy for Myocardial Infarction and Heart Failure: A Comprehensive Systematic Review and Critical Analysis. Cureus. 2024;16(5):e59474. PMID: 38832190

Disclaimer

The information on this page is for educational purposes only and is not intended as medical advice. ALIV therapies are not intended to diagnose, treat, cure, or prevent any disease, including cardiovascular disease, coronary artery disease, hypertension, heart failure, atherosclerosis, peripheral arterial disease, cerebrovascular disease, or any other cardiac or vascular condition. This protocol is integrative supportive care provided alongside — not as a replacement for — specialist cardiology, internal medicine, and emergency care. All cardiology-prescribed medications must be continued as directed; ALIV does not prescribe, modify, or replace cardiology medications including statins, antihypertensives, antiplatelets, anticoagulants, anti-arrhythmics, or any cardiac drug regimen. ALIV does not claim to prevent heart attack, stroke, or any cardiovascular event. Advanced biomarker testing including lipoprotein(a) and hsCRP provides information; clinical action on biomarkers is the responsibility of your treating physician. SS-31, Thymosin Alpha-1, and BPC-157 peptide therapies are investigational and not FDA-approved for cardiovascular indications. Autologous cell therapy is offered as anti-aging regenerative support, not as a cardiovascular treatment; evidence is early. Acute cardiac symptoms (chest pain, severe breathlessness, palpitations, sudden weakness) require emergency medical evaluation, not this protocol. Please consult a qualified healthcare professional before starting any therapy programme.